Lead Product(s): Forigerimod
Therapeutic Area: Immunology
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Avion Pharmaceuticals
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Agreement February 06, 2020
Avion and ImmuPharma to meet with the FDA in Q1 2020 to discuss guidance on a new optimised international Phase III trial protocol.